Business Description
Gyre Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US4037831033
Description
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 13.98 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.03 | |||||
| Debt-to-EBITDA | 0.15 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | 19.03 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Future 3-5Y Total Revenue Growth Rate | 20.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 48 | |||||
| 9-Day RSI | 43.58 | |||||
| 14-Day RSI | 42.98 | |||||
| 6-1 Month Momentum % | 34.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.72 | |||||
| Quick Ratio | 3.29 | |||||
| Cash Ratio | 1.71 | |||||
| Days Inventory | 489.66 | |||||
| Days Sales Outstanding | 59.43 | |||||
| Days Payable | 29.03 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.05 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 96.23 | |||||
| Operating Margin % | 9.88 | |||||
| Net Margin % | -84.57 | |||||
| FCF Margin % | -2.22 | |||||
| ROE % | -216.19 | |||||
| ROA % | -73.3 | |||||
| ROIC % | 15.04 | |||||
| ROC (Joel Greenblatt) % | 31.19 | |||||
| ROCE % | 10 | |||||
| Years of Profitability over Past 10-Year | 2 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 16.5 | |||||
| PS Ratio | 9.69 | |||||
| PB Ratio | 14.59 | |||||
| Price-to-Tangible-Book | 16.06 | |||||
| Price-to-Operating-Cash-Flow | 298.61 | |||||
| EV-to-EBIT | 95.26 | |||||
| EV-to-EBITDA | 83.75 | |||||
| EV-to-Revenue | 9.41 | |||||
| EV-to-FCF | -432.32 | |||||
| Earnings Yield (Greenblatt) % | 1.05 | |||||
| FCF Yield % | -0.23 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Gyre Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 96.292 | ||
| EPS (TTM) (€) | -1.163 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 42.98 | ||
| 14-Day ATR (€) | 0.582884 | ||
| 20-Day SMA (€) | 11.5375 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 8.7 - 24.2 | ||
| Shares Outstanding (Mil) | 85.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Gyre Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Gyre Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Gyre Therapeutics Inc Frequently Asked Questions
What is Gyre Therapeutics Inc(FRA:L9S)'s stock price today?
The current price of FRA:L9S is €10.60. The 52 week high of FRA:L9S is €24.20 and 52 week low is €8.70.
When is next earnings date of Gyre Therapeutics Inc(FRA:L9S)?
The next earnings date of Gyre Therapeutics Inc(FRA:L9S) is 2025-03-26 Est..
Does Gyre Therapeutics Inc(FRA:L9S) pay dividends? If so, how much?
Gyre Therapeutics Inc(FRA:L9S) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers